PROCEPT BioRobotics faces securities class action claims on behalf of investors who bought PRCT securities between Feb. 28, 2024 and Feb. 25, 2026, with Sept. 22, 2026 as the deadline to seek lead plaintiff status. The complaints allege the company used discounts and weak inventory controls to pull forward Aquablation handpiece sales, while actual procedure demand lagged and handpiece sales exceeded procedures by 8% to 16% each quarter since Q1 2023, eventually leaving more than 10,000 excess units in the field. Plaintiffs say the issue became clearer when PROCEPT disclosed actual procedure data on Feb. 25, 2026 and reported a roughly 30% sequential drop in quarterly unit sales to about 9,400 from about 13,200 in Q3 2025. New filings also emphasize Wall Street concern that recurring handpiece revenue may have overstated underlying procedure demand, after management had attributed earlier volatility to factors including saline shortages, and note that PRCT later fell more than 75% from a class period high of about $100 to less than $25.